Immunovant (IMVT) earnings

Earnings (net income) · fiscal 2026
-$505.61M

Immunovant (IMVT) reported net income of -$505.61M in fiscal 2026 (the year ended March 31, 2026). In fiscal 2025 the figure was -$413.84M. Figures as of 17 Nov 2026, 23:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2026
-$505.61M
Highest on record
-$28.60Mfiscal 2019
Lowest on record
-$505.61Mfiscal 2026
Fiscal years on record
82019–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant earnings, in more detail

Across the 8 fiscal years on record (2019–2026), the highest was -$28.60M in fiscal 2019 and the lowest -$505.61M in fiscal 2026.

History · 8 fiscal years

Earnings (net income) by fiscal year

Immunovant earnings, year by year

Immunovant (IMVT) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2026-$505.61M—
2025-$413.84M—
2024-$259.34M—
2023-$210.96M—
2022-$156.73M—
2021-$107.43M—
2020-$66.39M—
2019-$28.60M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of Immunovant and comparable companies
CompanyEarnings (net income)Fiscal year
Bausch + Lomb BLCO-$360.00M2025
Amneal Pharmaceuticals AMRX$72.06M2025
Caris Life Sciences CAI-$68.09M2025
Immunovant IMVT-$505.61M2026
Axsome Therapeutics AXSM-$183.17M2025
Chemed CHE$265.24M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant earnings: questions and answers

What is Immunovant's net income?

Immunovant (IMVT) reported net income of -$505.61M in fiscal 2026 (the year ended March 31, 2026). In fiscal 2025 the figure was -$413.84M.

What are the highest and lowest net income figures on record for Immunovant?

Across the 8 fiscal years on record (2019–2026), the highest was -$28.60M in fiscal 2019 and the lowest -$505.61M in fiscal 2026.

How is Immunovant's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) earnings”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.